All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anti-SARS-CoV-2 polyclonal antibodies
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2021
Details:
Grifols will begin a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex®-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VLPs based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: SpyBiotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 27, 2020
Details:
SpyBiotech selected 3P Biopharmaceuticals in June 2019 to manufacture a cGMP batch of their virus-like-particle carrier with the goal of completing production in 2021. This carrier will be used to display antigens from different pathogens.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anti-SARS-CoV-2 hyperimmune globulin therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Details:
The company has started production of its anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using the plasma of people who have overcome the disease. It is the first specific drug developed to combat COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Genistein
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2020
Details:
More than 75 patients affected by COVID-19 have been successfully treated with Lactyferrin, to date with moderate to severe clinical features.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RUTI vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: RUTI
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2020
Details:
RUTI® vaccine is administered by subcutaneous injection, is safe and is in advanced clinical stages in India and Ukraine for the treatment of tuberculosis and antibiotic-resistant tuberculosis, and also as an enhancer of the anticancer response in bladder cancer patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anti-SARS-CoV-2 hyperimmune globulin therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 25, 2020
Details:
Grifols will volunteer its expertise and resources in the areas of plasma collection using its network of plasma donor centers; test and qualify donors in conjunction with other health agencies.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
